Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 38Other hematologic neoplasm 36Plasma cell 29Myeloid 19CNS 17Sarcoma 10Dermatologic 9Gastrointestinal 7Other solid neoplasm 6Gynecologic 6Genitourinary 4Classical hematology 2Other 1Breast 1

Conditions

Multiple Myeloma 1Mucositis 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Metformin 2rosiglitazone-metformin combination 1mirabegron 1lorcaserin 1exemestane 1atezolizumab 1angiotensin I (1-7) 1Traumeel S 1Tirzepatide 1TIC10 compound 1Sodium Chloride 1Rosiglitazone 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Melphalan 1Leflunomide 1Hydroquinones 1Fish Oils 1Fibroblast Growth Factor 7 1Drug Therapy 1Docosahexaenoic Acids 1Cisplatin 1Cholestyramine Resin 1CBLB502 1Ascorbic Acid 1Acupuncture Therapy 1ART123 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Melphalan × Other × Clear all
NCT00482846 2014-04-15

Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma

Barbara Ann Karmanos Cancer Institute

Phase 1 Completed
38 enrolled
OtherPlasma cell

Multiple Myeloma, Mucositis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡